Summary
This phase III randomised controlled trial reports 24-month follow-up data from the EV-301 study comparing enfortumab vedotin with platinum-based chemotherapy in patients with advanced urothelial carcinoma who had received prior treatment. The study, published in Annals of Oncology in 2023, extends understanding of long-term outcomes for this immunoconjugate therapy in a previously under-treated population with limited therapeutic options.
UK applicability
As this is an oncology trial, direct applicability to UK farming systems or food production is not relevant. However, findings on cancer treatment outcomes may inform UK National Health Service commissioning and clinical practice guidelines for urological malignancies.
Key measures
Overall survival, progression-free survival, objective response rate, duration of response, adverse events and serious adverse events at 24-month follow-up
Outcomes reported
The study reported 24-month efficacy and safety outcomes comparing enfortumab vedotin with chemotherapy in patients with previously treated advanced urothelial carcinoma. Long-term survival, progression-free survival, and adverse event profiles were assessed.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.